Our Sponsors 2023
We would like to thank our sponsors for their support in making the 39th Annual Conference German Association of the Study of the Liver (GASL) a reality!
Your GASL Organizing Team
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe, Bylvay has been approved for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with global Phase 3 trials in Alagille syndrome (ALGS) and biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden.
Advanz Pharma Specialty Medicine Deutschland GmbH
ADVANZ PHARMA is a global pharmaceutical
company with a strategic focus on specialty and hospital pharmaceuticals. We are committed to improving patients’ lives by providing and enhancing the medicines they depend on.
AstraZeneca is a global, science-led BioPharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines. Our purpose is to push the boundaries of science to deliver life-changing medicines.
Institut AllergoSan Deutschland GmbH
With over 30 years of experience, Institut AllergoSan, a centre of excellence within microbiome research, is dedicated to the research and development of products made of natural substances such as probiotic bacteria, plant extracts, and minerals.
Dr. Falk Pharma GmbH
Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, Dr. Falk Pharma has ten affiliates in Europe and Australia and is continuously growing. The family-owned business has its headquarters and R&D facilities in Freiburg, Germany, its pharmaceutical products are manufactured in Europe, mainly at sites in Germany, France, Italy and Switzerland.
W. L. Gore & Associates GmbH
Gore engineers medical devices that treat a range of cardiovascular and other health conditions. With more than 50 million medical devices implanted over the course of more than 45 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives.
Alexion Pharma Germany GmbH
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Alexion Pharma Germany is located in Munich, Germany. For more information, please visit: alexion.de.